Novartis AG's Tabrecta (capmatinib) is the first therapy approved by the US Food and Drug Administration (FDA) targeting metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14). The drug was approved by the FDA on 6 May along with a FoundationOne companion diagnostic to detect METex14 mutations.
The mutations only affect a small number of patients with NSCLC – about 4,000-5,000 patients a year in the US,...
Welcome to Scrip
Create an account to read this article
Already a subscriber?